IP Library Granted Patent US 9,205,069
Granted Patent B2
US 9,205,069 · App. 13/254,235 · Granted Dec 8, 2015

Inhibitors of anaphase promoting complex activity

Inventors: Randall King (Newton, MA); Xing Zeng (Jamaica Plain, MA); Shantanu Gaur (Canonsburg, PA)
Assignee: President and Fellows of Harvard College
A61K31/198A61K31/155A61K31/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,205,069
App. No.
13/254,235
Granted
Dec 8, 2015
Kind
B2
Abstract

The invention provides an anti-proliferative composition comprising a non-peptide analog of the C-terminal isoleucine-arginine (IR) tail motif of an activator of an anaphase promoting complex (APC). The invention further provides methods of inhibiting the ubiquitination activity of the APC by administering compositions of the invention.

Claims (9)

1. A method for inhibiting a ubiquitination activity of an APC in a mammalian cell comprising a spindle assembly checkpoint (SAC), comprising administering an effective amount of a non-peptide analog of a C-terminal IR motif of an activator of an APC to a mammalian cell to inhibit a degradation of a substrate of an APC.

2. A method for inhibiting a ubiquitination activity of an APC in a mammalian cell comprising a spindle assembly checkpoint (SAC), comprising administering an effective amount of a non-peptide analog of a C-terminal IR motif of an activator of an APC to a mammalian cell to induce a cell cycle checkpoint.

3. The method of claim 1 or 2 , wherein said analog is tosyl-L-arginine methylester (TAME).

4. The method of claim 1 or 2 , wherein said analog is tosyl-L-arginine methylester (TAME), tosyl-L-arginine amide (TAA), tosyl-L-lysine methylester (TLME), tosyl-L-arginine (TAOH), acetyl-L-arginine methylester (AAME), Benzoyl-L-arginine amide (BAA), tosyl-L-arginine t-butyl-ester (TATE), or Benzoyl-L-arginine methylester (BAME).

5. The method of claim 1 , wherein said cell is human.

6. The method of claim 1 , wherein said analog contacts a component of a tetratricopeptide repeats (TPR) subcomplex of an APC.

7. The method of claim 6 , wherein said component of a TPR subcomplex is APC3/Cdc27, APC6, APC7, or APC8.

8. The method of claim 2 , wherein said cell cycle checkpoint is a spindle assembly checkpoint (SAC).

9. The method of claim 1 or 2 , wherein said activator of an APC is Cdc20 or Cdh1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 3, 2014
From: GAUR, SHANTANU; KING, RANDALL W.; ZENG, XING
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 032590/0163 →
CONFIRMATORY LICENSE Recorded Jan 23, 2012
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027579/0351 →
Continuity (2)
Provisional Application 61157942 · Mar 6, 2009
Related Publication 20120115948A1 · May 10, 2012